SG81977A1 - Substituted tricyclics - Google Patents

Substituted tricyclics

Info

Publication number
SG81977A1
SG81977A1 SG9901869A SG1999001869A SG81977A1 SG 81977 A1 SG81977 A1 SG 81977A1 SG 9901869 A SG9901869 A SG 9901869A SG 1999001869 A SG1999001869 A SG 1999001869A SG 81977 A1 SG81977 A1 SG 81977A1
Authority
SG
Singapore
Prior art keywords
substituted tricyclics
tricyclics
substituted
Prior art date
Application number
SG9901869A
Other languages
English (en)
Inventor
Benjamin Alan Anderson
Nicholas James Bach
Jolie Anne Bastian
Nancy Kay Harn
Richard Waltz Harper
Gary Alan Hite
Michael Dean Kinnick
Ho-Shen Lin
Richard James Loncharich
John Mcneill Mcgill Iii
Edward David Mihelich
John Michael Junior Morin
Michael Leroy Phillips
Michael Enrico Richett
Daniel Jon Sall
Jason Scott Sawyer
Richard Walter Schevitz
Robert Theodore Vasileff
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG81977A1 publication Critical patent/SG81977A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG9901869A 1998-04-17 1999-04-16 Substituted tricyclics SG81977A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
SG81977A1 true SG81977A1 (en) 2001-07-24

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
SG9901869A SG81977A1 (en) 1998-04-17 1999-04-16 Substituted tricyclics
SG9901681A SG81976A1 (en) 1998-04-17 1999-04-16 Substituted tricyclics

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG9901681A SG81976A1 (en) 1998-04-17 1999-04-16 Substituted tricyclics

Country Status (30)

Country Link
EP (2) EP0950657B1 (no)
JP (2) JPH11322713A (no)
KR (2) KR19990083232A (no)
CN (1) CN1149193C (no)
AR (2) AR018593A1 (no)
AT (2) ATE271037T1 (no)
AU (2) AU753547B2 (no)
BR (2) BR9901279A (no)
CA (2) CA2269246C (no)
CO (2) CO5011054A1 (no)
CZ (2) CZ137099A3 (no)
DE (2) DE69918590T2 (no)
DK (1) DK0950657T3 (no)
DZ (1) DZ2769A1 (no)
EA (2) EA002347B1 (no)
ES (2) ES2222663T3 (no)
HU (2) HUP9901220A3 (no)
ID (2) ID23761A (no)
IL (2) IL129485A0 (no)
NO (2) NO314400B1 (no)
NZ (3) NZ507564A (no)
PE (2) PE20000432A1 (no)
PL (2) PL332566A1 (no)
PT (1) PT950657E (no)
SG (2) SG81977A1 (no)
SI (1) SI0950657T1 (no)
TR (2) TR199900853A2 (no)
TW (1) TWI238160B (no)
YU (2) YU19199A (no)
ZA (2) ZA992772B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011670A4 (en) * 1997-08-28 2004-10-27 Lilly Co Eli PROCESS FOR TREATING NON-RHUMATOID POLYARTHRITIS
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
WO2000037022A2 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
JP2003505372A (ja) * 1999-07-19 2003-02-12 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビター
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
ES2294003T3 (es) * 2000-06-29 2008-04-01 Anthera Pharmaceuticals, Inc. Remedios contra el cancer.
US20040102442A1 (en) * 2000-06-29 2004-05-27 Kohji Hanasaki Remedies for alzheimer's disease
WO2002000256A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cirrhosis
AU2001272915A1 (en) * 2000-07-14 2002-01-30 Eli Lilly And Company Method for treating sepsis
JP2004518659A (ja) 2000-12-18 2004-06-24 イーライ・リリー・アンド・カンパニー 新規ｓＰＬＡ２インヒビター
EP1395554B1 (en) 2001-03-28 2007-02-14 Eli Lilly And Company Substituted carbazoles as inhibitors of spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
AU2009230127B2 (en) 2008-03-26 2011-12-22 Daiichi Sankyo Company, Limited Novel tetrahydroisoquinoline derivative
PE20091838A1 (es) 2008-04-09 2009-12-18 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso
EP2379538A4 (en) 2009-01-22 2013-01-02 Orchid Res Lab Ltd HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
ES2493916T3 (es) 2009-04-07 2014-09-12 Infinity Pharmaceuticals, Inc. Inhibidores de hidrolasa de amida de ácidos grasos
MX336742B (es) 2010-02-03 2016-01-29 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso.
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
BR112015012138A2 (pt) 2012-11-30 2017-07-11 Ge Healthcare Ltd composição, método para obtenção de uma composição, método de formação de imagem in vivo, e, kit
CA2889642A1 (en) 2012-11-30 2014-06-05 Ge Healthcare Limited Zinc halide mediated cyclization process leading to tricyclic indoles
EP3248230B1 (de) * 2015-01-20 2020-05-06 cynora GmbH Verwendung organischer moleküle in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839806A1 (en) * 1996-10-30 1998-05-06 Eli Lilly And Company Substituted tricyclics
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5472978A (en) * 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
KR19990072110A (ko) * 1995-12-13 1999-09-27 피터 지. 스트링거 Spla2 억제제인 나프틸 아세트아미드
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839806A1 (en) * 1996-10-30 1998-05-06 Eli Lilly And Company Substituted tricyclics
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease

Also Published As

Publication number Publication date
NO991822L (no) 1999-10-18
KR19990083232A (ko) 1999-11-25
AU753547B2 (en) 2002-10-24
IL129483A0 (en) 2000-02-29
NO991822D0 (no) 1999-04-16
CA2269262A1 (en) 1999-10-17
CO5031247A1 (es) 2001-04-27
PE20000476A1 (es) 2000-06-02
AR018186A1 (es) 2001-10-31
PE20000432A1 (es) 2000-05-23
ES2222663T3 (es) 2005-02-01
EP0952149A2 (en) 1999-10-27
PL332565A1 (en) 1999-10-25
TR199900853A3 (tr) 1999-11-22
CZ137099A3 (cs) 1999-11-17
ATE271037T1 (de) 2004-07-15
HU9901221A (hu) 2000-04-28
NZ335251A (en) 2000-11-24
EA199900301A2 (ru) 1999-10-28
NZ335253A (en) 2000-11-24
KR19990083233A (ko) 1999-11-25
EA199900303A3 (ru) 2000-04-24
JP4435330B2 (ja) 2010-03-17
EA002816B1 (ru) 2002-10-31
DZ2769A1 (fr) 2003-12-01
BR9901279A (pt) 2000-05-02
KR100586761B1 (ko) 2006-06-08
HU9901221D0 (en) 1999-06-28
CA2269246C (en) 2009-08-25
HU9901220A (hu) 2000-04-28
YU18999A (sh) 2002-08-12
NO314400B1 (no) 2003-03-17
EP0952149B1 (en) 2004-06-09
AU753436B2 (en) 2002-10-17
DE69918590D1 (de) 2004-08-19
AU2381799A (en) 1999-10-28
EP0950657A2 (en) 1999-10-20
PT950657E (pt) 2004-11-30
SG81976A1 (en) 2001-07-24
TR199900843A2 (xx) 2000-02-21
NO991821L (no) 1999-10-18
TWI238160B (en) 2005-08-21
NO991821D0 (no) 1999-04-16
ID23287A (id) 2000-04-05
HUP9901220A3 (en) 2001-11-28
EA199900301A3 (ru) 2000-04-24
ZA992772B (en) 2002-07-16
BR9902365A (pt) 2001-04-24
ATE268756T1 (de) 2004-06-15
IL129485A0 (en) 2000-02-29
AR018593A1 (es) 2001-11-28
DE69918590T2 (de) 2005-07-21
ES2226286T3 (es) 2005-03-16
YU19199A (sh) 2002-08-12
SI0950657T1 (en) 2005-02-28
DE69917833D1 (de) 2004-07-15
CZ136999A3 (cs) 1999-11-17
PL332566A1 (en) 1999-10-25
ID23761A (id) 2000-05-11
CO5011054A1 (es) 2001-02-28
EP0950657A3 (en) 2001-08-16
EP0952149A3 (en) 2001-08-16
AU2381999A (en) 1999-10-28
HUP9901221A3 (en) 2001-11-28
DK0950657T3 (da) 2004-11-22
CN1149193C (zh) 2004-05-12
JP2000026416A (ja) 2000-01-25
TR199900853A2 (xx) 1999-11-22
DE69917833T2 (de) 2005-07-14
CA2269246A1 (en) 1999-10-17
NZ507564A (en) 2002-10-25
HU9901220D0 (en) 1999-06-28
EP0950657B1 (en) 2004-07-14
EA199900303A2 (ru) 1999-10-28
JPH11322713A (ja) 1999-11-24
EA002347B1 (ru) 2002-04-25
ZA992771B (en) 2002-04-18
NO312240B1 (no) 2002-04-15
CN1253948A (zh) 2000-05-24

Similar Documents

Publication Publication Date Title
SG81976A1 (en) Substituted tricyclics
DE59912932D1 (en) Arylphenylsubstituierte cyclische ketoenole
DE59912303D1 (en) Arylphenylsubstituierte cyclische ketoenole
GB2342193B (en) Addition circuitry
PL341642A1 (en) Novel macrolydes
DE69904335D1 (en) Aminomethylcarbonsäurederivate
DE69835235D1 (en) Thermoplastische silikonelastomere
DE59903023D1 (en) Perorale wirkstoff-suspension
IL129481A0 (en) Substituted tricyclics
DE59914151D1 (en) Arylalkanoylpyridazine
SG106035A1 (en) Substituted tricyclics
EP1068213A4 (en) SILOXANES WITH AMINO-ORGANIC FUNCTIONAL GROUP
DE60042897D1 (en) Photovervielfacherröhre
DE59904407D1 (en) Chromanderivate
GB9815401D0 (en) Earphone-microphone-earmuff-assembly
GB9816729D0 (en) Substituted cyclohexylaminopyrimidines
HK1039937A1 (zh) 取代的3-硫代氨基甲酰基吡唑類化合物
PL347397A1 (en) Substituted 3-aryl-pyrazoles
DE59900495D1 (en) Multimetalloxidmassen
DE59900471D1 (en) Inchbremseinrichtung
PL345866A1 (en) Substituted cyclooctadepsipeptides
HK1039335A1 (zh) 取代的苯甲酰基環已二酮類化合物
DE59905941D1 (en) Methoximinophenylessigsäureamide
DE59911094D1 (en) Tryptase-inhibitoren
GB9827486D0 (en) Arm-bands